Head-to-head evidence
Cabotegravir vs VH4524184
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Cabotegravir · Vocabria / Cabenuva / Apretude
Marketed by ViiV Healthcare
NCT02720094 · Phase 2/3 · completed
The trial randomized 4,570 participants to cabotegravir or active-controlled TDF/FTC treatment and used quadruple blinding of participants, clinicians, investigators, and outcome assessors. Its hard clinical primary efficacy endpoint—documented incident HIV infection—was met, with 13 versus 39 infections and a hazard ratio of 0.340 (95% CI 0.18–0.62; p=0.0005).
Next expected readout: October 2026 · NCT05660980 (registry estimate)
VH4524184
Developed by ViiV Healthcare
NCT06214052 · Phase 2 · completed
The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported.
Next expected readout: June 2027 · NCT07202546 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir's landscape · VH4524184's landscape